N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial

W. W. Tan, D. W. Hillman, M. Salim, D. W. Northfelt, D. M. Anderson, P. J. Stella, R. Niedringhaus, A. M. Bernath, S. S. Gamini, F. Palmieri, E. A. Perez

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Fingerprint Dive into the research topics of 'N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences